

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A high molecular weight aptamer composition comprising:
 - (a) a nucleic acid comprising two or more aptamers, and
 - (b) a stabilizing moiety comprising a linking moiety, wherein the linking moiety is not a nucleic acid molecule.
2. (Original) The aptamer composition of claim 1, wherein the linking moiety comprises a polyalkylene glycol.
3. (Original) The aptamer composition of claim 2, wherein the linking moiety comprises polyethylene glycol (PEG).
4. (Original) The aptamer composition of claim 3, wherein the nucleic acid comprises first and second aptamers.
5. (Original) The aptamer composition of claim 4, wherein the first and second aptamers are linked by the PEG linking moiety, and further wherein the primary structure of the aptamer composition comprises a linear arrangement in which the first aptamer is linked to a first terminus of the PEG linking moiety and the second aptamer is linked to a second terminus of the PEG linking moiety.
6. (Original) The aptamer composition of claim 3, wherein the polyethylene glycol (PEG) linking moiety is multi-activated.
7. (Original) The aptamer composition of claim 6, wherein the PEG linking moiety is bi-activated.

Wilson, et al.
U.S.S.N. 10/718,833

8. (Original) The aptamer composition of claim 1, wherein the aptamer composition is capable of binding to platelet derived growth factor (PDGF).

9. (Cancelled)

10. (Original) The aptamer composition of claim 1, wherein the high molecular weight aptamer composition has a molecular weight selected from the group consisting of greater than 10 kD, greater than 20 kD, greater than 40 kD and greater than 80 kD.

11. - 57. (Cancelled)